Welcome to STN International! Enter x:x

LOGINID: ssspta1621vxo

#### PASSWORD:

\* \* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \* \* SESSION RESUMED IN FILE 'CAPLUS' AT 16:10:16 ON 06 JUL 2007 FILE 'CAPLUS' ENTERED AT 16:10:16 ON 06 JUL 2007 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	54.87	227.65
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
•	ENTRY	SESSION
CA SUBSCRIBER PRICE	-7.02	-7.02

=>
Uploading C:\Program Files\Stnexp\Queries\910.str

L7 STRUCTURE UPLOADED

=> d L7 HAS NO ANSWERS L7 STF

G1 O, N

Structure attributes must be viewed using STN Express query preparation.

=> s 17 full
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 16:10:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 58545 TO ITERATE

100.0% PROCESSED 58545 ITERATIONS 35 ANSWERS

SEARCH TIME: 00.00.01

L8 35 SEA SSS FUL L7

L9 2 L8

=> d 1-2 ibib abs hitstr

L9 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2004:964817 CAPLUS

DOCUMENT NUMBER:

141:410756

TITLE:

Preparation of macrocyclic compounds for the treatment

of inflammation and autoimmune disorders

INVENTOR(S):

Chiba, Kenichi; Du, Hong; Eguchi, Yoshihito; Fujita, Masanori; Goto, Masaki; Gusovsky, Fabian; Harmange, Jean-Christophe; Inoue, Atsushi; Kawada, Megumi; Kawai, Takatoshi; Kawakami, Yoshiyuki; Kimura,

Akifumi; Kotake, Makoto; Kuboi, Yoshikazu; Matsushima, Tomohiro; Mizui, Yoshiharu; Muramoto, Kenzo; Sakurai, Hideki; Shen, Yong-chun; Shirota, Hiroshi; Spyvee, Mark; Tanaka, Isao; Wang, John; Wood, Ray; Yamamoto,

Satoshi; Yoneda, Naoki

PATENT ASSIGNEE(S):

Japan

SOURCE:

U.S. Pat. Appl. Publ., 299 pp., Cont.-in-part of Appl.

No. PCT/US03/07377.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PAT	ENT	NO.			KIN	D	DATE			APPL		ION :			Ď.	ATE		
	<del>2004</del> 2003				A1 A1		2004 2003			US 2 WO 2	003-	6579	10		_	0030 0030		
			AG,	ΔT.											_			
			CR,															
			HR,															
			LT,															
			PT,									TJ,	TM,	TN,	TR,	TT,	TZ,	
		•	UG,		•		•	•	•	•				±				
	RW:		GM,															
			ΚZ,															
			FR,															
		BF,	ВJ,	CF,	CG,													
WO	2005	0237	92		A2		2005	0317	1	WO 2	004-1	US29	196		2	0040	909	
WO	2005	0237	92		A3		2005	0623										
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
		CN,	co,	CR,	CU,	CŻ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KZ,	LC,	
			LR,															
			NZ,															
			TM,															
	RW:		GH,															
			BY,															
			ES,															
			SK,															
			TD,		,	,	/	,	,	J,	J. 1,	J.,,	~2 <i>,</i>	J.,	,,,,,	,	1111,	
ישדמר	ממג י	•	•						,	110 2		2620	220	,	n 2/	2020	200	

US 2002-380711P P 20020514 WO 2003-US307377 A2 20030307 US 2003-657910 A 20030909

OTHER SOURCE(S):

MARPAT 141:410756

AB Macrocyclic compds. of formula I [R1 = H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.; R2, R3 = H, halo, (substituted) OH, alkyl, aryl, etc.; R1R2, R1R3 = alkylene; R4 = H, halo; R5 = H, protecting group, prodrug; R6, R7, R11 = H, (substituted) OH; R8, R9 = H, halo, (substituted) OH, alkoxy, etc.; R10 = H, (substituted) OH, (substituted) NH2; n = 0-2; X = absent, O, NH, N-alkyl, CH2, S; Y, Z = CH, O, CO, NH, etc.] are prepared for the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis. In certain embodiments, methods for the treatment of various disorders including inflammatory or autoimmune disorders comprise systemically (e.g., orally) administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. Thus, II was prepared in several steps. Some of the compds. inhibited NF-κB with IC50 values < 10μM.

IT 603039-45-8P 603045-38-1P 603045-40-5P 603045-42-7P 603045-44-9P 603045-46-1P 603151-24-2P 603151-32-2P 603151-34-4P 603959-45-1P 603985-37-1P 603985-63-3P 603985-65-5P 603985-69-9P 603985-71-3P 603985-72-4P 603985-73-5P 603985-74-6P 603985-75-7P 603985-77-9P 603985-78-0P 603986-04-5P 603987-34-4P 603987-35-5P 603987-75-3P 603987-93-5P 603988-36-9P 791101-13-8P 791101-14-9P 791101-15-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocyclic compds. for the treatment of inflammatory or autoimmune disorders)

RN 603039-45-8 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(trifluoromethyl)-, (5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 603045-38-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(dimethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603045-40-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603045-42-7 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 603045-44-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(ethylamino)-6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603045-46-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-(1H-imidazol-1-yl)ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603151-24-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603151-32-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603151-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4S,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603959-45-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(phenylmethyl)-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

RN 603985-37-1. CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-13,14-dimethoxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603985-63-3 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(4-methoxyphenyl)methoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 603985-65-5 CAPLUS

CN Acetamide, N-[3-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

RN 603985-69-9 CAPLUS

CN Acetamide, N-[3-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603985-71-3 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(methylsulfonyl)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 603985-72-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,14,16-tetrahydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

RN 603985-73-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(2-pyridinylamino)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

$$\begin{array}{c|c} H \\ N \\ CH_2) \ 3 \end{array} \begin{array}{c} OH \\ E \\ S \\ H \end{array} \begin{array}{c} OH \\ S \\ R \end{array} \begin{array}{c} OH \\ Z \\ \end{array}$$

RN 603985-74-6 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(2-azidoethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603985-75-7 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-[(1H-imidazol-2-ylmethyl)amino]ethoxy]-3,4-dimethyl-,

PAGE 1-B

<u>\_\_0</u>

RN 603985-77-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[4-[(1H-imidazol-2-ylmethyl)amino]butoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-B

\_0

RN 603985-78-0 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(difluoromethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

RN 603986-04-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(2,2,2-trifluoroethoxy)-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603987-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603987-35-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

RN 603987-75-3 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 603987-93-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-, (3S,4R,5E,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 603988-36-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-10-(methoxymethoxy)-3,4-dimethyl-,

RN 791101-13-8 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-ethoxy-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 791101-14-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[2-(methylamino)ethoxy]-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-[2-(dimethylamino)ethoxy]-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:737744 CAPLUS

DOCUMENT NUMBER: 139:261090

TITLE: Preparation of macrocyclic compounds for use in

pharmaceutical and cosmetic compositions which regulate various genes involved in immune and

inflammatory responses

INVENTOR(S): Boivin, Roch; Chiba, Kenichi; Davis, Heather A.;

Diepitro, Lucian; Du, Hong; Eguchi, Yoshihito; Fujita, Masanori; Gilbert, Sandra; Goto, Masaki; Harmange, Jean Christophe; Inoue, Atsushi; Jiang, Yimin; Kawada, Megumi; Kawai, Takatoshi; Kawakami, Yoshiyuki; Kimura, Akifumi; Kotake, Makoto; Kuboi, Yoshikazu; Lemelin, Charles; Li, Xiang-yi; Matsushima, Tomohiro; Mizui, Yoshiharu; Sakurai, Hideki; Schiller, Shawn; Shen, Yongchun; Spyvee, Mark; Tanaka, Isao; Wang, Yuan;

Yamamoto, Satoshi; Yoneda, Naoki; Kobayashi, Seiichi

PATENT ASSIGNEE(S): Eisai Co. Ltd., Japan; et al.

SOURCE: PCT Int. Appl., 438 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PAT	PATENT NO.				KIND DATE				APPL	I CAT	ION 1	NO.		DATE			
WO	2003	0764:	24		A1 · 20030918			1	WO 2	 003-1	us73	 77		2	0030	 307	
	W:							ΑZ,									
								DM,									
								IS,									
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	ТJ,	TM,	TN,	TR,	TT,	TZ,
		UA,	UG,	US,	UZ,	VC,	VŇ,	YU,	ZA,	ZM,	ZW						
	RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
		KG,	ΚZ,	MD,	RU,	ТJ,	TM,	AT,	BE,	BG,	·CH,	CY,	CZ,	DE,	DK,	EE,	ES,
		FI,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR,
		BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	TD,	TG
CA	2478	065	•		<b>A</b> 1	;	2003	0918	. (	CA 2	003-	2478	065		2	0030	307
AU	2003	2246	72		<b>A</b> 1		2003	0922	1	AU 2	003-2	2246	72		2	0030	307
BR	2003	0081	13		Α		2005	0209		BR 2	003-	8113			2	0030	307

EP 1507773	A1	20050223	EP 2003-721353		20030307
R: AT, BE, C	H, DE, DK	, ES, FR,	GB, GR, IT, LI, LU,	NL,	SE, MC, PT,
IE, SI, L	T, LV, FI	, RO, MK,	CY, AL, TR, BG, CZ,	EE,	HU, SK
JP 2005519954	T	20050707	JP 2003-574642		20030307
CN 1653059	A	20050810	CN 2003-810248		20030307
US 2004224936❤	. A1	20041111	US 2003-657910		20030909
IN 2004KN01270	Α	20060714	IN 2004-KN1270		20040830
NO 2004004256 -	· A	20041207	NO 2004-4256		20041007
US 2006247448 🕳	<b>A</b> 1	20061102	US 2004-507067		20041110
PRIORITY APPLN. INFO.:			US 2002-362883P	Р	20020308
			US 2002-380711P	P	20020514.
			WO 2003-US7377	W	20030307
OMILED COLLDGE (C) -	M2 D D 2 M	120.26100	20		

OTHER SOURCE(S):

MARPAT 139:261090

GI

Macrocyclic lactones and lactams, such as I [R1 = H, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; R2, R3 = H, OH, halogen, protected hydroxyl, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; R1R2 or R1R3 = 3-8 membered alicyclic ring; R4 = H, halogen; R5 = H, hydroxyl protecting group, linked prodrug; R6, R7 = H, OH, protected hydroxyl; R8, R9, R10, R11 = H, OH, NH2, alkoxy, alkylamino, etc.; X = O, NH, S, CH2, etc.; R8R9 = fused ring, such as furan or imidazole; Y-Z = CH:CH, NHCO, etc.], were prepared for a variety of therapeutic and cosmetic uses, such as antitumor and anti-inflammatory agents and treatment of skin photodamage. These macrocycles are claimed for use as NF-kB, AP-1, protein kinase, cancer cell proliferation and solid tumor angiogenesis inhibitors and for use in the treatment of inflammation, cancer, psoriasis, skin photodamage, restenosis as stent coatings, rheumatoid arthritis, asthma, sepsis, inflammatory bowel disease, atopic dermatitis, Crohn's disease, autoimmune disorders and for treatment of gastrointestinal, esophageal, tracheal/bronchial, urethral and vascular obstructions wherein the lumen of a body passageway is expanded. Thus, macrocyclic lactone II, designated as ER 803064, was prepared via a multistep synthetic sequence with included a macrolactonization reaction of III to form the desired lactone ring. The

prepared macrocycles were assayed for their effect on TNF- $\alpha$  and  $\beta$ -actin placental alkaline phosphatase transcription using human acute monocytic leukemia cells. IT 603044-46-8P 603045-38-1P 603045-40-5P 603045-42-7P 603045-44-9P, ER 807563 603045-45-0P 603045-46-1P 603151-24-2P, ER 803064 603151-32-2P 603151-34-4P, ER 804019 603985-37-1P 603985-63-3P 603985-64-4P 603985-65-5P 603985-69-9P 603985-70-2P, ER 804606 603985-72-4P 603985-73-5P 603985-74-6P 603985-75-7P 603985-76-8P 603985-77-9P 603985-78-0P 603986-04-5P, ER 804387 603987-34-4P 603987-35-5P 603987-75-3P 603987-93-5P, ER 806821 603988-36-9P RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of macrocyclic compds. for use in pharmaceutical and cosmetic compns. which regulate various genes involved in immune and inflammatory responses) RN 603044-46-8 CAPLUS CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-, (3S,4R,5E,8R,9R,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 603045-38-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(dimethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603045-40-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603045-42-7 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 603045-44-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(ethylamino)-6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 603045-45-0 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-[(methylsulfonyl)oxy]propoxy]-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603045-46-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-(1H-imidazol-1-yl)ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 603151-24-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603151-32-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603151-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4S,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603985-37-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-13,14-dimethoxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CAINDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 603985-63-3 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(4-methoxyphenyl)methoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603985-64-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(2,3-dihydroxypropoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603985-65-5 CAPLUS

CN Acetamide, N-[3-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603985-69-9 CAPLUS

CN Acetamide, N-[3-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603985-70-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[2-(4-morpholinyl)ethoxy]-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 603985-72-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,14,16-tetrahydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 603985-73-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(2-pyridinylamino)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603985-74-6 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(2-azidoethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 603985-75-7 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-[(1H-imidazol-2-ylmethyl)amino]ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

=0

RN 603985-76-8 CAPLUS

CN Methanesulfonamide, N-[2-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603985-77-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[4-[(1H-imidazol-2-ylmethyl)amino]butoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-B

\_0

RN 603985-78-0 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(difluoromethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI)

RN 603986-04-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(2,2,2-trifluoroethoxy)-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603987-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603987-35-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(ethylamino)-3,4,9,10-

tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 603987-75-3 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603987-93-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-, (3S,4R,5E,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603988-36-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-10-(methoxymethoxy)-3,4-dimethyl-, (3S,4R,5Z,8S,9R,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

IT 603039-45-8P 603959-45-1P 603985-71-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of macrocyclic compds. for use in pharmaceutical and cosmetic compns. which regulate various genes involved in immune and inflammatory responses)

RN 603039-45-8 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(trifluoromethyl)-, (5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603959-45-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(phenylmethyl)-, (3S,4R,5Z,8S,9S,11E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 603985-71-3 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(methylsulfonyl)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

6

REFERENCE COUNT:

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

# **Refine Search**

#### Search Results -

Terms	Documents
MACROCYCLIC COMPOUND.TI. AND 540/\$	21

US Pre-Grant Publication Full-Text Database

US Patents Full-Text Database US OCR Full-Text Database

Database:

EPO Abstracts Database JPO Abstracts Database Derwent World Patents Index

**IBM Technical Disclosure Bulletins** 

Search:

<b>ւ</b> 7		•
		<b>-</b>

Refine Search

Recall Text

Clear

Interrupt

### **Search History**

DATE: Friday, July 06, 2007 **Purge Queries** Printable Copy Create Case

Set Name side by side		Hit Count	Set Name result set
DB=PG	PB, USPT, USOC, EPAB, JPAB, DWPI, TDBD; PLUR = YEAR + SPAR + SP	S; OP=ADJ	•
<u>L7</u>	MACROCYCLIC COMPOUND.TI. AND 540/\$	21	<u>L7</u>
DB=PG	PB; PLUR=YES; OP=ADJ		
<u>L6</u>	20040224936 or 20040004256 or 20060247448	3	<u>L6</u>
<u>L5</u>	2004224936 or 2004004256 or 2006247448	0	<u>L5</u>
DB=PG	PB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YE	S; OP=ADJ	
<u>L4</u>	L3 and (562/\$ or 560/\$ or 564/\$)	3	<u>L4</u>
<u>L3</u>	L2 and acrylic\$8 and palladium	7	<u>L3</u>
<u>L2</u>	polyhalo\$8 cinnamic acid	7	<u>L2</u>
L1	polhalo\$8 cinnamic acid	0	L1

**END OF SEARCH HISTORY** 

## **Hit List**

First Hit Clear Generate Collection Print Fwd Refs Bkwd Refs
Generate OACS

Search Results - Record(s) 1 through 10 of 21 returned.

☐ 1. Document ID: US 20070117154 A1

L7: Entry 1 of 21

File: PGPB

May 24, 2007

PGPUB-DOCUMENT-NUMBER: 20070117154

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20070117154 A1

TITLE: Combinatorial Synthesis of Libraries of Macrocyclic Compounds Useful in Drug

Discovery

PUBLICATION-DATE: May 24, 2007

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY North Hatley CA Deslongchamps; Pierre Dory; Yves Canton d'Eaton Cookshire CA Berthiaume; Gilles Pte-Claire CA CA Ouellet: Luc Sherbrooke Lan; Ruoxi Fleurimont CA

US-CL-CURRENT: 435/7.1; 514/183, 540/455

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. De
									•			

2. Document ID: US 20060205638 A1

L7: Entry 2 of 21

File: PGPB

Sep 14, 2006

PGPUB-DOCUMENT-NUMBER: 20060205638

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060205638 A1

TITLE: PROCESS FOR PREPARING MACROCYCLIC COMPOUNDS

PUBLICATION-DATE: September 14, 2006

INVENTOR-INFORMATION:

COUNTRY NAME CITY STATE Busacca; Carl Alan Poughkeepsie US NY Gallou; Fabrice Paris CTFR Haddad; Nizar Danbury VA US

Hossain; Azad	Glen Allen	CT	US
Kapadia; Suresh R.	Danbury	VA	US
Liu; Jianxiu	Richmond	CT	US
Senanayake; Chris	Brookfield	CT	US
Wei; Xudong	Ridgefield	CT	US
Yee; Nathan K.	Danbury		US

US-CL-CURRENT: 514/9; 530/317, 540/460

Full Title Citation	Front Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Drawt De

3. Document ID: US 20060062728 A1

L7: Entry 3 of 21

File: PGPB

Mar 23, 2006

Dec 1, 2005

PGPUB-DOCUMENT-NUMBER: 20060062728

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060062728 A1

TITLE: Multifunctional cross-bridged tetraaza macrocyclic compounds and methods of

making and using

PUBLICATION-DATE: March 23, 2006

INVENTOR-INFORMATION:

CITY STATE COUNTRY NAME

Brogan; John Bucknam Niskayuna NY US

US-CL-CURRENT: 424/1.49; 534/11, 540/465, 540/473

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw, De
Г	4.	Docume	nt ID:	US 20	050267018	A1						

File: PGPB

PGPUB-DOCUMENT-NUMBER: 20050267018

PGPUB-FILING-TYPE: new

L7: Entry 4 of 21

DOCUMENT-IDENTIFIER: US 20050267018 A1

TITLE: Macrocyclic compounds as inhibitors of viral replication

PUBLICATION-DATE: December 1, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Blatt, Lawrence M.	San Francisco	CA	US
Andrews, Steven W.	Longmont	CO	US
Condroski, Kevin R.	Broomfield	CO	US
Doherty, George A.	Superior	CO	US

Jiang, Yutong	Longmont	CO	US
Josey, John A.	Longmont	CO	US
Kennedy, April L.	Denver	CO	US
Madduru, Machender R.	Boulder	CO	US
Stengel, Peter J.	Longmont	CO	US
Wenglowsky, Steven M.	Boulder	CO	US
Woodard, Benjamin T.	Golden	CO	US
Woodard, Laura	Golden	CO	US

US-CL-CURRENT: 514/9; 514/310, 530/317, 540/460

1: 5. Document ID: US 20050209135 AT

L7: Entry 5 of 21

File: PGPB

Sep 22, 2005

PGPUB-DOCUMENT-NUMBER: 20050209135

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050209135 A1

TITLE: Process for preparing macrocyclic compounds

PUBLICATION-DATE: September 22, 2005

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Busacca, Carl Alan	Poughkeepsie	NY	US
Farina, Vittorio	Ridgefield	CT	US
Gallou, Fabrice	Danbury	CT	US
Haddad, Nizar	Danbury	CT	US
Wang, Xiao-Jun	Danbury	CT	US
Wei, Xudong	Ridgefield	CT	US
Xu, Jinghua	Bethel	CT	US.
Xu, Yibo	New Milford	CT	US
Yee, Nathan K.	Danbury	CT	US
Zhang, Li	New Milford	CT	US

US-CL-CURRENT: 514/10; 514/314, 530/317, 540/465

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, D

6. Document ID: US 20050049234 A1

L7: Entry 6 of 21

File: PGPB

Mar 3, 2005

PGPUB-DOCUMENT-NUMBER: 20050049234

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050049234 A1

Page 4 of 5 Record List Display

TITLE: Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery

PUBLICATION-DATE: March 3, 2005

INVENTOR - INFORMATION:

CITY STATE COUNTRY NAME Deslongchamps, Pierre Sherbrooke MΑ CA Dory, Yves Cookshire CA Berthiaume, Gilles Pointe-Claire CA CA Ouellet, Luc Sherbrooke Arlington US Lan, Ruoxi

US-CL-CURRENT: <u>514/183</u>; <u>540/460</u>

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, De

7. Document ID: US 20040115724 A1

L7: Entry 7 of 21

File: PGPB Jun 17, 2004

PGPUB-DOCUMENT-NUMBER: 20040115724

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040115724 A1

TITLE: Macrocyclic compounds and their use

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY

Lowik, Dennis Cambridge GB Lowe, Christopher Robin Cambridge GB

US-CL-CURRENT: 435/7.1; 540/472

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, De
										,		

8. Document ID: US 7148347 B2

L7: Entry 8 of 21 File: USPT Dec 12, 2006

US-PAT-NO: 7148347

DOCUMENT-IDENTIFIER: US 7148347 B2


TITLE: Process for preparing macrocyclic compounds.

PRIOR-PUBLICATION:

DOC-ID DATE

US 20050049187 A1 March 3, 2005

Page 5 of 5



**Display Format:** |-**Change Format** 

Previous Page Next Page Go to Doc#

### **Hit List**

First Hit Clear Generate Collection Print Fwd Refs Bkwd Refs
Generate OACS

Search Results - Record(s) 11 through 20 of 21 returned.

☐ 11. Document ID: US 6107482 A

L7: Entry 11 of 21

File: USPT

Aug 22, 2000

US-PAT-NO: 6107482

DOCUMENT-IDENTIFIER: US 6107482 A

\*\* See image for Certificate of Correction \*\*

TITLE: Nitrogenous macrocyclic compounds

Full Title Citation Front Review Classification Date Reference ANTERIOS STATES & Claims KMC Draw De

☐ 12. Document ID: US 6054580 A

L7: Entry 12 of 21

File: USPT

Apr 25, 2000

US-PAT-NO: 6054580

DOCUMENT-IDENTIFIER: US 6054580 A

TITLE: Long-lived homogenous amide containing macrocyclic compounds

Full Title Citation Front Review Classification Date Reference Reference Claims KMC Draw. De

13. Document ID: US 5871709 A

L7: Entry 13 of 21

File: USPT

Feb 16, 1999

US-PAT-NO: 5871709

DOCUMENT-IDENTIFIER: US 5871709 A

TITLE: <u>Macrocyclic compounds</u> as complexing compounds or agents, complexes of metal ions therewith and use thereof as contrast media for diagnostics and therapeutics

Full Title Citation Front Review Classification Date Reference

☐ 14. Document ID: US 5583131 A

L7: Entry 14 of 21

File: USPT

Dec 10, 1996

US-PAT-NO: 5583131

DOCUMENT-IDENTIFIER: US 5583131 A


TITLE: Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity

Full Title Citation Front Review Classification Date Reference Ref

US-PAT-NO: 5580900

DOCUMENT-IDENTIFIER: US 5580900 A


TITLE: Macrocyclic compounds



US-PAT-NO: 5523402

DOCUMENT-IDENTIFIER: US 5523402 A


TITLE: Tripyridyl macrocyclic compounds



US-PAT-NO: 5376663

DOCUMENT-IDENTIFIER: US 5376663 A


TITLE: Macrocyclic compounds



US-PAT-NO: 5326861

DOCUMENT-IDENTIFIER: US 5326861 A

TITLE: Preparation of organic <u>macrocyclic compounds</u>



☐ 19. Document ID: US 5296489 A

L7: Entry 19 of 21

File: USPT


Mar 22, 1994

US-PAT-NO: 5296489

DOCUMENT-IDENTIFIER: US 5296489 A

\*\* See image for Certificate of Correction \*\*


TITLE: Immunosuppressive macrocyclic compounds



US-PAT-NO: 5179087

DOCUMENT-IDENTIFIER: US 5179087 A

TITLE: Macrocyclic compounds



Display Format: - Change Format

Previous Page Next Page Go to Doc#

# **Hit List**

First Hit Clear Generate Collection Print Fwd Refs Bkwd Refs

Generate OACS

**Search Results -** Record(s) 21 through 21 of 21 returned.

21. Document ID: US 4960882 A

L7: Entry 21 of 21


File: USPT

Oct 2, 1990

US-PAT-NO: 4960882

DOCUMENT-IDENTIFIER: US 4960882 A

TITLE: Proton ionizable macrocyclic compounds



Display Format: - Change Format

<u>Previous Page</u>

Next Page

Go to Doc#